Evidence map›Paper›PMID 39754105›Full record

ArticleMicrobial cell factories2025

Metabolic engineering of Priestia megaterium for 2'-fucosyllactose production.

Bu-Soo Park, Jihee Yoon, Jun-Min Lee, Sang-Hyeok Cho, Yoojeong Choi, Byung-Kwan Cho, Min-Kyu Oh

Abstract read
In one paragraph

Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bu-Soo Park *Department of Chemical & Biological Engineering, Korea University, Seoul, 136-763, Korea.
Jihee Yoon *Samyang Corp., 295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea.
Jun-Min Lee *Department of Chemical & Biological Engineering, Korea University, Seoul, 136-763, Korea.
Sang-Hyeok ChoDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
Yoojeong ChoiDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
Byung-Kwan ChoDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea. bcho@kaist.ac.kr.ORCID http://orcid.org/0000-0003-4788-4184
Min-Kyu OhDepartment of Chemical & Biological Engineering, Korea University, Seoul, 136-763, Korea. mkoh@korea.ac.kr.

Funding

Ministry of Trade, Industry and Energy 20026226
6 · The paper itself

Abstract

background2'-Fucosyllactose (2'-FL) is a predominant human milk oligosaccharide that significantly enhances infant nutrition and immune health. This study addresses the need for a safe and economical production of 2'-FL by employing Generally Recognized As Safe (GRAS) microbial strain, Priestia megaterium ATCC 14581. This strain was chosen for its robust growth and established safety profile and attributing suitable for industrial-scale production.

resultsThe engineering targets included the deletion of the lacZ gene to prevent lactose metabolism interference, introduction of α-1,2-fucosyltransferase derived from the non-pathogenic strain, and optimization of the GDP-L-fucose biosynthesis pathway through the overexpression of manA and manC. These changes, coupled with improvements in lactose uptake and utilization through random mutagenesis, led to a high 2'-FL yield of 28.6 g/L in fed-batch fermentation, highlighting the potential of our metabolic engineering strategies on P. megaterium.

conclusionsThe GRAS strain P. megaterium ATCC 14581 was successfully engineered to overproduce 2'-FL, a valuable human milk oligosaccharide, through a series of genetic modifications and metabolic pathway optimizations. This work underscores the feasibility of using GRAS strains for the production of oligosaccharides, paving the way for safer and more efficient methods in biotechnological applications. Future studies could explore additional genetic modifications and optimization of fermentation conditions of the strain to further enhance 2'-FL yield and scalability.

Indexed as

FucosyltransferasesMetabolic EngineeringTrisaccharidesBacillus megateriumFermentationHumansLactoseMilk, Human2'-fucosyllactoseFucosyltransferasesLactoseTrisaccharides2’-fucosyllactoseGRASHMOMetabolic engineeringPriestia megaterium ATCC 14581α-1,2-fucosyltransferase

Identifiers

PMID39754105
PMCPMC11699682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.